Our study showed that gemigliptin significantly improved the expression of renal tubular injury biomarkers and vascular calcification levels among patients with DKD; however, gemigliptin did not affect renal function or coronary calcification compared with those observed in the control (Journal of Diabetes Research)
Diabetes News
Tag: CKD
Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study
This study identified multiple prediction models to predict albuminuria, diabetic kidney disease, chronic kidney disease, and end stage renal disease. In the external validation, discrimination and calibration for albuminuria, diabetic kidney disease, and chronic kidney disease varied considerably across prediction horizons and models (BMJ)
Type 2 diabetes in adults: management – SGLT2 inhibitors for chronic kidney disease (update)
You can now review and comment on this draft guideline (NICE)
Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations
While eGFR testing rates are uniformly high among people with type 2 diabetes, testing rates for uACR are suboptimal and highly variable across and within the organizations examined. Guideline-recommended uACR testing should increase detection of CKD (Diabetes Care)
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Among patients treated with renin–angiotensin–aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia (European Heart Journal)
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Among patients with stage 4 CKD and albuminuria, dapagliflozin’s benefits were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks (JASN)
Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe
DKD (using the KDIGO 2012 classification) and rapid eGFR decline were highly prevalent among adults attending a hospital-based diabetes clinic in a predominantly Caucasian Northern European country. The burden was greater for adults with type 2 diabetes. Expected as well as potentially novel clinical predictors were identified (BMJ)
Deficits in the Skeletal Muscle Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to Functional Decline
Our results indicate that T2DM-induced CKD progression impairs physical function, with implications for altered metabolic transcriptional networks and mitochondrial functional deficits as primary mechanistic factors early in CKD progression in T2DM (Diabetes)
Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
Medications shown to slow progression of CKD include renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists and, more recently, non-steroidal mineralocorticoid receptor antagonists (Diabetes Therapy)
Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial
Licogliflozin treatment results in significantly increased UGE and favorable changes in urinary electrolytes and hemodynamics in patients with varying degrees of CKD (eGFR≥45 mL/min/1.73 m2) (Diabetes, Obesity and Metabolism)
Sodium‐glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease
The degree of BP reduction after SGLT2 inhibitor treatment influenced renal composite outcomes in Japanese T2DM patients with CKD, confirming the importance of blood pressure management in T2DM patients with CKD, even when they are under SGLT2 inhibitor treatment (Journal of Diabetes Investigation)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:
Dapagliflozin reduces the risks of major adverse kidney and cardiovascular events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease (The Lancet)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events (NEJM)
Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (Annals of Internal Medicine)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (NEJM)
Dapagliflozin in Patients with Chronic Kidney Disease
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (NEJM)
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease
Our results confirmed that blood pressure management status after treatment with SGLT2 inhibitors influences the extent of change in urinary albumin-creatinine ratio. Stricter blood pressure management is needed to allow the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (Journal of Diabetes Research)
A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease
Patients with co-morbid diabetes and kidney disease have education gaps on the management of, and complications of diabetes and kidney disease. Interventions aimed at improving patient education need to be delivered through education resources co-developed by patients and health staff. A targeted education resource in the form of a DVD, addressing these needs, may potentially close these gaps (BMC Nephrology)
Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease
Metformin may be safer for use in CKD than previously considered and may lower the risk of death and cardiovascular events in individuals with stage 3 CKD (Diabetes, Obesity and Metabolism)
Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
Evidence concerning the efficacy and safety of glucose‐lowering agents for people with diabetes and CKD is limited. SGLT2 inhibitors and GLP‐1 agonists are probably efficacious for lowering glucose levels. Other potential effects of SGLT2 inhibitors include lower BP, lower potassium levels and a reduced risk of heart failure but an increased risk of genital infections. The safety of GLP‐1 agonists is uncertain (Cochrane Library)
Glycosmedia is also available as an App: